Superselective intra-arterial cerebral infusion of chemotherapeutics after osmotic blood–brain barrier disruption in newly diagnosed or recurrent glioblastoma: technical insights and clinical outcomes from a single-center experience

医学 胶质母细胞瘤 单中心 血脑屏障 麻醉 外科 重症监护医学 内科学 中枢神经系统 癌症研究
作者
Christian Ferreira,Marcio Yuri Ferreira,Faith Singh,Tamika Wong,S. Bokil,Sara Massimo,Julianna Cavallaro,Olivia Albers,Randy S. D’Amico,David J. Langer,John A. Boockvar,Yafell Serulle
出处
期刊:Journal of NeuroInterventional Surgery [BMJ]
卷期号:: jnis-023068
标识
DOI:10.1136/jnis-2025-023068
摘要

Background Newly diagnosed glioblastoma (ndGBM) remains one of the most challenging malignancies to treat. Since the majority of patients experience tumor recurrence (rGBM) after first-line therapy, advancements in both initial and salvage treatments are essential. Objective We report our single-center experience on the feasibility and safety of superselective intra-arterial cerebral infusion (SIACI) with bevacizumab or cetuximab after osmotic blood–brain barrier disruption (oBBBd). Methods Partial results of three distinct trials (anonymized for blinded review) were analyzed. All patients were histopathologically confirmed to have either ndGBM or previously diagnosed ndGBM that progressed to rGBM despite standard therapy and had aKarnofsky Performance Status (KPS)≥70. All patients were admitted on the same day of the surgery, and the intervention followed similar steps in all included patients. Under general anesthesia, after oBBBd with mannitol, patients received SIACI. Results Between October 2014 and March 2024, 70 patients with a mean age of 56.2±12.4 years (range: 19–78) underwent successful treatment, encompassing 139 SIACIs and 246 infusions. All planned SIACIs were completed successfully. Forty-one patients with rGBM received bevacizumab-SIACI, 7 with ndGBM bevacizumab-SIACI, and 22 with ndGBM cetuximab-SIACI. In 133 of 139 SIACIs (95.7%), patients were discharged home with a length of stay of 1 day. The incidence of patients who experienced procedure-related and drug-related adverse events was 11.4% and 8.6%, respectively. No procedure-related deaths occurred. Conclusion In our single-center experience, comprising the largest cohort of bevacizumab or cetuximab SIACI treatment for rGBM and ndGBM, this promising and cutting-edge intervention is highly feasible and safe.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Sencetich发布了新的文献求助10
1秒前
我爱科研科研爱我完成签到,获得积分10
2秒前
Shaylee完成签到,获得积分10
2秒前
2秒前
研友_VZG7GZ应助坚强傲晴采纳,获得10
2秒前
4秒前
5秒前
Akim应助EddieDream采纳,获得10
5秒前
研友_ngkyGn应助山野采纳,获得10
5秒前
邸泽阳发布了新的文献求助10
6秒前
沉静丹寒完成签到,获得积分10
7秒前
啊哈哈哈完成签到 ,获得积分10
7秒前
xiu_ye完成签到,获得积分10
7秒前
7秒前
7秒前
8秒前
852应助小坤同学采纳,获得10
9秒前
沉静丹寒发布了新的文献求助30
9秒前
77sucy发布了新的文献求助10
10秒前
慕青应助awaer采纳,获得10
10秒前
锡昱完成签到,获得积分10
10秒前
Jasper应助linmo采纳,获得10
11秒前
张雷举报花开富贵求助涉嫌违规
11秒前
wanci应助jyylrl采纳,获得10
11秒前
12秒前
MchemG应助科研通管家采纳,获得10
13秒前
13秒前
完美世界应助科研通管家采纳,获得10
13秒前
华仔应助科研通管家采纳,获得10
13秒前
13秒前
坦率的匪应助科研通管家采纳,获得10
13秒前
慕青应助科研通管家采纳,获得10
13秒前
13秒前
1111应助科研通管家采纳,获得10
13秒前
天天快乐应助科研通管家采纳,获得10
13秒前
酷波er应助科研通管家采纳,获得10
13秒前
13秒前
顾矜应助科研通管家采纳,获得10
13秒前
情怀应助科研通管家采纳,获得10
14秒前
MchemG应助科研通管家采纳,获得10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988827
求助须知:如何正确求助?哪些是违规求助? 3531183
关于积分的说明 11252671
捐赠科研通 3269809
什么是DOI,文献DOI怎么找? 1804780
邀请新用户注册赠送积分活动 881885
科研通“疑难数据库(出版商)”最低求助积分说明 809021